Key points are not available for this paper at this time.
This Viewpoint discusses the need to achieve consensus around management strategies for patients with hyperlipidemia when proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors enter the marketplace.
Shrank et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: